Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

If Economists Are Correct About the Future of AI, Here Are 2 Global ETFs to Buy -- and 2 to Avoid ↗

October 22, 2026

A recent survey shows reasons to be bullish on international stocks. But some global ETFs look more bullish than others.

Invesco recently launched QQI, an ETF tracking the Nasdaq International Innovators 100 Index, offering tech- and healthcare-heavy exposure to non-U.S. growth companies with higher costs and lower...

There's a New Q in Town: Invesco's ETF Targets International Innovators ↗

October 22, 2026

Via MarketBeat

Topics ETFs

Genentech Presents New Pivotal Trial Data Across Broad Neuroimmunology Portfolio at MSToronto2026

October 21, 2026

From Genentech

Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech? ↗

October 21, 2026

This beaten-down biotech has a better story than its stock chart suggests.

Genentech to Present Pivotal Data at ESMO 2026, Showcasing Advances Across Its Lung and Breast Cancer Late-Stage Portfolio

October 19, 2026

From Genentech

FDA Approves Genentech’s Enspryng, a First-in-Class IL-6R Inhibitor, as the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)

October 16, 2026

From Genentech

Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss

October 10, 2026

From Genentech

The sell-offs for both of these beaten-down biotech stocks appear to be overdone.

Alnylam vs. Ionis: Here's the Better Bad-News Buy ↗

October 10, 2026

FDA Approves Genentech’s Tecentriq in Combination With a Fluoropyrimidine and Oxaliplatin for the Adjuvant Treatment of a Certain Type of Stage III Colon Cancer

October 09, 2026

From Genentech

Genentech and Breastcancer.org Say It’s “About Damn Time” We Talk About What Happens When Initial Breast Cancer Treatment Ends

October 01, 2026

From Genentech

Genentech Presents New Data at EURETINA, Highlighting Vabysmo’s Real-World Effectiveness and Safety Across Major Retinal Conditions

October 01, 2026

From Genentech

Genentech’s Giredestrant Combination Significantly Improved Progression-Free Survival in ER-positive Advanced Breast Cancer in Phase III evERA Data Published in The New England Journal of Medicine

October 01, 2026

From Genentech

Roche is increasingly looking like a notable contender in this fast-growing area.

Could This Company Challenge Eli Lilly and Novo Nordisk in the Weight Loss Market? ↗

September 30, 2026

Genentech’s Fenebrutinib Is the First BTK Inhibitor to Receive U.S. FDA Filing Acceptance in Both Relapsing and Primary Progressive Multiple Sclerosis

September 30, 2026

From Genentech

Genentech Breaks Ground on $750 Million Manufacturing Expansion in Hillsboro, Oregon

September 28, 2026

From Genentech

Positive Interim Data Shows Genentech’s Sefaxersen Significantly Reduces Proteinuria in People With IgA Nephropathy (IgAN)

September 23, 2026

From Genentech

The past couple of years have been challenging for the company, but there is a light at the end of the tunnel.

Is Regeneron Stock a Bargain Below $800? ↗

September 22, 2026

Genentech Announces Positive Phase II Results for Dual GLP-1/GIP Receptor Agonist Enicepatide in People Living With Type 2 Diabetes and Overweight or Obesity

Topics Intellectual Property

September 22, 2026

From Genentech

BioNTech Threw in the Towel on Its Colorectal Cancer Vaccine Trial. Should Investors Be Worried? ↗

September 18, 2026

BioNTech's recent pipeline setback is a real cause of concern. But investors shouldn't panic.

Genentech and Roche Announce Grand Opening of Boston R&D Innovation Center

September 17, 2026

From Genentech

Genentech’s Lunsumio-Based Regimen Significantly Improves Progression-Free Survival in Follicular Lymphoma in Phase III CELESTIMO Study

September 17, 2026

From Genentech

U.S. FDA Grants Priority Review for Genentech’s Enspryng for MOGAD, an Autoimmune Disease With No Approved Treatments

September 10, 2026

From Genentech

A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach

September 08, 2026

InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial

September 08, 2026

InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial

September 08, 2026

MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial

September 08, 2026

FDA approved Revolution Medicines' RASONQUE for pancreatic cancer, but RVMD stock stayed flat as investors had priced in the news early, with rising expenses now in focus.

A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach

September 08, 2026

From BioMedWire

Via GlobeNewswire

Revolution Medicines Got Its Breakthrough—What Moves It Next? ↗

September 04, 2026

Via MarketBeat

Here's Why Ionis Pharmaceuticals' Steep Sell-off Was Overdone ↗

September 03, 2026

This biotech stock looks like a great candidate to buy on the admittedly steep dip.